Cell Death and Disease (Sep 2021)

Modulation of oxidative phosphorylation augments antineoplastic activity of mitotic aurora kinase inhibition

  • Zijian Zhang,
  • Deshun Zeng,
  • Wei Zhang,
  • Ailin Chen,
  • Jie Lei,
  • Fang Liu,
  • Bing Deng,
  • Junxiao Zhuo,
  • Bin He,
  • Min Yan,
  • Xinxing Lei,
  • Shulan Wang,
  • Eric W.-F. Lam,
  • Quentin Liu,
  • Zifeng Wang

DOI
https://doi.org/10.1038/s41419-021-04190-w
Journal volume & issue
Vol. 12, no. 10
pp. 1 – 15

Abstract

Read online

Abstract Uncontrolled mitosis is one of the most important features of cancer, and mitotic kinases are thought to be ideal targets for anticancer therapeutics. However, despite numerous clinical attempts spanning decades, clinical trials for mitotic kinase-targeting agents have generally stalled in the late stages due to limited therapeutic effectiveness. Alisertib (MLN8237) is a promising oral mitotic aurora kinase A (AURKA, Aurora-A) selective inhibitor, which is currently under several clinical evaluations but has failed in its first Phase III trial due to inadequate efficacy. In this study, we performed genome-wide CRISPR/Cas9-based screening to identify vulnerable biological processes associated with alisertib in breast cancer MDA-MB-231 cells. The result indicated that alisertib treated cancer cells are more sensitive to the genetic perturbation of oxidative phosphorylation (OXPHOS). Mechanistic investigation indicated that alisertib treatment, as well as other mitotic kinase inhibitors, rapidly reduces the intracellular ATP level to generate a status that is highly addictive to OXPHOS. Furthermore, the combinational inhibition of mitotic kinase and OXPHOS by alisertib, and metformin respectively, generates severe energy exhaustion in mitotic cells that consequently triggers cell death. The combination regimen also enhanced tumor regression significantly in vivo. This suggests that targeting OXPHOS by metformin is a potential strategy for promoting the therapeutic effects of mitotic kinase inhibitors through the joint targeting of mitosis and cellular energy homeostasis.